Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,782 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.
Landen JW, Zhao Q, Cohen S, Borrie M, Woodward M, Billing CB Jr, Bales K, Alvey C, McCush F, Yang J, Kupiec JW, Bednar MM. Landen JW, et al. Among authors: woodward m. Clin Neuropharmacol. 2013 Jan-Feb;36(1):14-23. doi: 10.1097/WNF.0b013e31827db49b. Clin Neuropharmacol. 2013. PMID: 23334070 Clinical Trial.
Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.
Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, Hager K, Andreasen N, Scarpini E, Liu-Seifert H, Case M, Dean RA, Hake A, Sundell K, Poole Hoffmann V, Carlson C, Khanna R, Mintun M, DeMattos R, Selzler KJ, Siemers E. Honig LS, et al. Among authors: woodward m. N Engl J Med. 2018 Jan 25;378(4):321-330. doi: 10.1056/NEJMoa1705971. N Engl J Med. 2018. PMID: 29365294 Free article. Clinical Trial.
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS; GRADUATE I and II Investigators and the Gantenerumab Study Group. Bateman RJ, et al. Among authors: woodward m. N Engl J Med. 2023 Nov 16;389(20):1862-1876. doi: 10.1056/NEJMoa2304430. N Engl J Med. 2023. PMID: 37966285 Clinical Trial.
Blood-based protein biomarkers for diagnosis of Alzheimer disease.
Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, Mondal A, Bedo J, Bush AI, Brown B, De Ruyck K, Ellis KA, Fowler C, Gupta VB, Head R, Macaulay SL, Pertile K, Rowe CC, Rembach A, Rodrigues M, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ames D, Masters CL, Martins RN; Alzheimer's Disease Neuroimaging Initiative; Australian Imaging Biomarker and Lifestyle Research Group. Doecke JD, et al. Arch Neurol. 2012 Oct;69(10):1318-25. doi: 10.1001/archneurol.2012.1282. Arch Neurol. 2012. PMID: 22801742 Free PMC article.
Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.
Burns DK, Alexander RC, Welsh-Bohmer KA, Culp M, Chiang C, O'Neil J, Evans RM, Harrigan P, Plassman BL, Burke JR, Wu J, Lutz MW, Haneline S, Schwarz AJ, Schneider LS, Yaffe K, Saunders AM, Ratti E; TOMMORROW study investigators. Burns DK, et al. Lancet Neurol. 2021 Jul;20(7):537-547. doi: 10.1016/S1474-4422(21)00043-0. Lancet Neurol. 2021. PMID: 34146512 Clinical Trial.
Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume.
Milicic L, Vacher M, Porter T, Doré V, Burnham SC, Bourgeat P, Shishegar R, Doecke J, Armstrong NJ, Tankard R, Maruff P, Masters CL, Rowe CC, Villemagne VL, Laws SM; Alzheimer’s Disease Neuroimaging Initiative (ADNI); Australian Imaging Biomarkers and Lifestyle (AIBL) Study. Milicic L, et al. Geroscience. 2022 Jun;44(3):1807-1823. doi: 10.1007/s11357-022-00558-8. Epub 2022 Apr 21. Geroscience. 2022. PMID: 35445885 Free PMC article.
A naturalistic study of galantamine for Alzheimer's disease.
Brodaty H, Woodward M, Boundy K, Barnes N, Allen G; NATURE Investigators. Brodaty H, et al. Among authors: woodward m. CNS Drugs. 2006;20(11):935-43. doi: 10.2165/00023210-200620110-00006. CNS Drugs. 2006. PMID: 17044730 Clinical Trial.
Predicting Alzheimer disease with β-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing.
Rowe CC, Bourgeat P, Ellis KA, Brown B, Lim YY, Mulligan R, Jones G, Maruff P, Woodward M, Price R, Robins P, Tochon-Danguy H, O'Keefe G, Pike KE, Yates P, Szoeke C, Salvado O, Macaulay SL, O'Meara T, Head R, Cobiac L, Savage G, Martins R, Masters CL, Ames D, Villemagne VL. Rowe CC, et al. Among authors: woodward m. Ann Neurol. 2013 Dec;74(6):905-13. doi: 10.1002/ana.24040. Ann Neurol. 2013. PMID: 24448836 Free article.
1,782 results